Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas

Delta variants (B.1.617.2, AY.2, and AY.3) have become the focus of intense international concern because they are causing widespread COVID-19 disease in Southeast Asia, Europe, the United States, and elsewhere (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html, last accessed: July 19, 2021; https://www.gov.uk/government/collections/new-sars-cov-2-variant, last accessed: July 19, 2021). For example, Delta has rapidly replaced the Alpha variant in the United Kingdom, previously the cause of virtually all COVID-19 cases in that country (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021, last accessed July 19, 2021; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed July 19, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also have become of considerable public health and biomedical interest worldwide^1-4. To study Delta and vaccine breakthrough cases in metropolitan Houston, we sequenced the genomes of 3,913 SARS-CoV-2 from patient samples acquired March 15, 2021 through July 3, 2021 using an Illumina NovaSeq 6000 instrument⁵. This period encompasses the time from initial identification of a Delta-related variant in our large Houston Methodist healthcare system until Delta variants became the majority (>58%) of all new cases. The sample is 91% of the 4,281 cases of COVID-19 diagnosed in our health system during this period. Delta variants were identified based on genome sequence data as designated by Pangolin (https://cov-lineages.org/resources/pangolin.html, last accessed July 19, 2021).

During the study period 213 patients were diagnosed with Delta variants, and 255 of the 3,913 patients (6.5%) met the CDC definition of vaccine breakthrough cases (Table 1A) (https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html, last accessed July 19, 2021). Breakthrough cases received either the Pfizer-BioNTech BNT162b2 (n = 213, 84%), Moderna mRNA-1273 (n = 34, 13%), or J&J/Janssen JNJ-78436735 (n = 5, 2%) vaccines, generally reflecting the supermajority of BNT162b2 vaccinations in our health system; vaccine type was not specified for three individuals. Three patients with Delta Plus (Delta plus the K417N spike amino acid substitution) were identified, all diagnosed in July. Consistent with extensive infections caused by Delta variants in Southeast Asia and elsewhere, several patients had very recent travel histories to countries with a high prevalence of these variants, suggesting acquisition abroad and importation into Houston. Patients with Delta variants were identified in 95 zip codes throughout the metropolitan area. A total of 69 Delta subvariants was identified, likely reflecting the large population sizes and genetic diversity of Delta globally and multiple introductions into the Houston area. Patients infected with the same subvariant usually lived in different zip codes and had no apparent epidemiological link, consistent with the ability of Delta to spread very rapidly.

There is a considerable lack of detailed information about patients in the United States with COVID-19 caused by Delta variants (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021, last accessed July 19, 2021). Compared to all other patients, there was no significant difference in median age, gender, admission rate, disease severity or hospital length of stay (Table 1A). However, Delta cases were significantly more likely to be Asian (supporting multiple recent entry points) and less likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values (a proxy for higher virus load, a finding consistent with the reported increased transmissibility of Delta variants) on initial diagnosis, and cause a significantly higher rate of vaccine breakthrough cases (19.7% compared to 5.8% for all other variants) (Table 1A).

We next examined metadata for the 255 vaccine breakthrough cases (Table 1B). Vaccinated patients had a significantly higher Ct, likely indicating lower virus load on initial diagnosis. A greater percentage of patients with Delta breakthrough cases was admitted to the hospital, but the number did not reach significance (Table 1B).

Our genome sequence data document a very rapid increase of Delta variant cases in metropolitan Houston and a considerable corresponding decrease of COVID-19 cases caused by Alpha, findings similar to epidemiologic trends observed in the UK. Delta was significantly more likely to cause a vaccine breakthrough case (Table 1A). However, importantly, only 6.5% of all COVID-19 cases occurred in fully immunized individuals, and relatively few of these patients required hospitalization. In the aggregate, our data add critical new information to the finding that these three vaccines are highly efficacious in decreasing severe COVID-19 disease, hospitalizations, and deaths.